The global lipid metabolism disease drug market is estimated to grow at a CAGR of nearly XX% during the forecast period. The key factor driving the growth of the global lipid metabolism disease drug market includes the rising prevalence of lipid metabolism disorders and increasing adoption of an unhealthy lifestyle. According to the National Organizations of Rare Disorders, in 2018, lipid metabolism disorders such as Gaucher disease accounted for the 6,000 patients in the US and accounting for more than 90% of cases among Caucasians. It is a liposomal storage disorder in which due to the lack of enzyme glucocerebrosidase, certain sugars containing fats get accumulated in the body. 

The lipid metabolism disorders such as Gaucher disease, Niemann-Pick Disease, and Tay-Sachs disease, include lipids which are fats or fats-like substances including fatty acids, oils, waxes, and cholesterol. In this disorder, the body fails to convert fats into energy that subsequently leads to the accumulation of fats in the body which damages the various parts of the body including the liver, spleen, brain, peripheral nervous system, and many more. There are several FDA-approved drugs for the treatment of lipid metabolism disorders. For instance, Cerdelga (eliglustat) manufactured by Genzyme, was approved by the US FDA in 2014, for the long-term treatment of patients suffering from Gaucher disease. In the past few years, new drugs such as icosaapent ethyl, bempedoic acid, are being tested for the treatment of statin tolerated patients and has shown huge potential. 

The key players contributing to the growth of the global lipid metabolism disease drug market by adopting various strategies such as product launches & developments, mergers and acquisition, partnerships, and agreements, include Merck Group, Novartis AG, Takeda Pharmaceutical, AstraZeneca, Boehringer Ingelheim, KOWA, Kythera, Fuji yakuhin, LG Life Science, Mitsubishi Tanabe Pharma among others. For instance, in 2019, Investigational New Drug (IND) application by IntraBio Inc. was approved by the US FDA for the clinical trial of IB1001-202 containing lead compound (IB1001) for the treatment of Tay-Sachs disease and Sandhoff Disease. 

Market Coverage

• The market number available for – 2020-2027
• Base year- 2020
• Forecast period- 2021-2027
• Segment Covered- 

o By Type

o By Application

o By Distribution Channel

• Regions covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

• Competitive Landscape- Merck KGaA, Novartis AG, Takeda Pharmaceutical Company Ltd., AstraZeneca Plc., Boehringer Ingelheim, among others. 
  

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Lipid Metabolism Disease Drug Market-segmentation

By Type

• OTC
• Rx Drugs

By Application

• Lipoprotein disorders
• Fatty acid oxidation defects
• Mitochondrial disorders
• Lysosomal storage disorders
• Peroxisomal disorders
• Purine and pyrimidine disorders
• Porphyria’s

By Distribution Channel

• Hospital
• Retail Pharmacy
• Online 
• Others

Global Lipid Metabolism Disease Drug Market-segmentation by region